How much does polatuzumab cost (typical US pricing)?
Polatuzumab vedotin (Polivy) is a prescription cancer therapy. The exact out-of-pocket cost depends heavily on the setting (hospital/inpatient vs. outpatient), dose/number of cycles, insurance coverage, and any patient assistance. Pricing details for Polivy change over time and can differ by payer and contract, so there is no single universal “price” that applies to everyone.
What determines the total cost of polatuzumab treatment?
Your final cost usually depends on:
- Dose based on body weight and the number of treatment cycles.
- Coverage structure (commercial insurance vs. Medicare/Medicaid).
- Whether the drug is billed as part of an outpatient drug package or through a separate line-item pharmacy billing.
- Any negotiated hospital/insurer contract pricing.
- Patient assistance programs or copay support that may reduce cost for eligible patients.
Where do people find current polatuzumab list price and payer pricing?
For the most up-to-date published numbers, people commonly check:
- The manufacturer’s pricing information and patient support pages for Polivy.
- Drug pricing databases that track list price and changes over time (which may still not reflect what insurers actually pay).
- Your insurer’s drug formulary and prior authorization requirements (these can strongly affect your cost).
What copay assistance or patient support options can reduce the price?
If you’re asking because the drug is expensive, the most practical “price” questions are often about eligibility for:
- Copay assistance for commercially insured patients.
- Coverage navigation help through the manufacturer or specialty pharmacies.
- Financial assistance for patients who qualify under program criteria.
Availability and eligibility rules change, so the best source is the current Polivy/polatuzumab support program pages.
Are there biosimilar or cheaper alternatives that affect polatuzumab price?
Polatuzumab is a branded antibody-drug conjugate; lower-cost alternatives (if any) depend on whether competing therapies or later entrants exist for the same indications. Competition can reduce net prices for payers over time, but a direct “cheaper equivalent” for polatuzumab itself is not guaranteed.
If you share your country/insurance, I can narrow the price question
Prices differ by country and insurance. Tell me:
- Your country (US/Canada/EU/other)
- Insurance type (commercial, Medicare, Medicaid, uninsured)
- Approximate weight and regimen/cycles (if you know it)
…and I can point you to the most relevant way to estimate the real-world cost you’re likely to pay.